Geron (NASDAQ:GERN) Price Target Cut to $4.00 by Analysts at Stifel Nicolaus

Geron (NASDAQ:GERN) had its target price reduced by Stifel Nicolaus from $8.00 to $4.00 in a report issued on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on GERN. Barclays reaffirmed an “overweight” rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a research note on Thursday. HC Wainwright downgraded shares of Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Needham & Company LLC decreased their target price on shares of Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $3.50 to $2.00 in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $5.68.

Geron Trading Up 1.1 %

GERN stock opened at $1.76 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a one year low of $1.46 and a one year high of $5.34. The company’s 50 day moving average price is $2.93 and its two-hundred day moving average price is $3.77. The company has a market capitalization of $1.06 billion, a PE ratio of -5.50 and a beta of 0.53.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. As a group, analysts predict that Geron will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of Geron

Hedge funds have recently modified their holdings of the business. SBI Securities Co. Ltd. bought a new stake in shares of Geron during the 4th quarter valued at $28,000. Integrated Wealth Concepts LLC bought a new stake in shares of Geron during the 4th quarter valued at $36,000. GF Fund Management CO. LTD. bought a new stake in shares of Geron during the 4th quarter valued at $45,000. Fifth Lane Capital LP bought a new stake in shares of Geron during the 4th quarter valued at $53,000. Finally, Readystate Asset Management LP bought a new stake in shares of Geron during the 3rd quarter valued at $58,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.